Peer-reviewedLicence not statedLancet Oncology4 Nov 2026

Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial

Jordi Remon
Paolo Bironzo
Nicolas Girard
Laurence Bigay-Game
Oscar Juan-Vidal
Javier de Castro
Noemí Reguart
Laurent Greillier
Sophie Cousin
Eric Dansin
Margarita Majem
Reyes Bernabé

8 more authors

Joaquin Mosquera Martinez
Marta Díaz
Alba Meya
Daniel Alcalá-López
Alicia García-Sanz
Luisella Righi
Silvia Novello
Benjamin Besse

Open at source PDF DOI Cite

Recurrent TFE3-Rearranged Renal Cell Carcinoma Responding to Pembrolizumab Plus Lenvatinib After Postoperative Pembrolizumab: A Case Report.
Masashi Fujimoto, Tomoyasu Sano, Yuta Sano +7
IJU case reports19 Oct 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC
Salvage Chemotherapy After Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
CHIHIRO FUSHIMI, ISAKU OKAMOTO, TAKASHI MATSUKI +15
In Vivo29 Oct 2026Peer-reviewedCC BY-NC-ND 4.0Full textGeneral medicinePMC
Pembrolizumab plus lenvatinib in the treatment of unresectable cutaneous angiosarcoma: a study protocol of multicentre, open-label phase II study (NCCH2213, PLAS)
Dai Ogata, Eiji Nakano, Naoya Yamazaki +10
BMJ Open9 Oct 2026Peer-reviewedCC BY-NC 4.0Full textOncologyCrossref
Circulating Tumor DNA Clearance Is Associated with Response and Survival in Metastatic Urothelial Carcinoma Treated with First-Line Enfortumab Vedotin Plus Pembrolizumab
Adam Khorasanchi, Sayan Mullick Chowdhury, Eric Fei Hong +19
Cancers3 Nov 2026Peer-reviewedCC BY 4.0OncologyCrossref
Treatment-Free Interval as a Prognostic Factor for Survival Outcomes in Patients with Advanced or Recurrent Endometrial Cancer Treated with Pembrolizumab Plus Lenvatinib: A Multi-Institutional Real-World Cohort Study
Chih-Wen Su, Shao-Jing Wang, Yu-Hsiang Shih +9
Cancers22 Sep 2026Peer-reviewedCC BYFull textOncologyEurope PMC

Cite

BibTeX RIS

BibTeX

@article{remon2026lenvatinib,
  title = {{Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial}},
  author = {Jordi Remon and Paolo Bironzo and Nicolas Girard and Laurence Bigay-Game and Oscar Juan-Vidal and Javier de Castro and Noemí Reguart and Laurent Greillier and Sophie Cousin and Eric Dansin and Margarita Majem and Reyes Bernabé and Joaquin Mosquera Martinez and Marta Díaz and Alba Meya and Daniel Alcalá-López and Alicia García-Sanz and Luisella Righi and Silvia Novello and Benjamin Besse},
  journal = {Lancet Oncology},
  year = {2026},
  month = nov,
  doi = {10.1016/s1470-2045(25)00300-6},
  url = {https://hal.science/hal-05851896v1},
}

RIS

TY  - JOUR
TI  - Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial
AU  - Jordi Remon
AU  - Paolo Bironzo
AU  - Nicolas Girard
AU  - Laurence Bigay-Game
AU  - Oscar Juan-Vidal
AU  - Javier de Castro
AU  - Noemí Reguart
AU  - Laurent Greillier
AU  - Sophie Cousin
AU  - Eric Dansin
AU  - Margarita Majem
AU  - Reyes Bernabé
AU  - Joaquin Mosquera Martinez
AU  - Marta Díaz
AU  - Alba Meya
AU  - Daniel Alcalá-López
AU  - Alicia García-Sanz
AU  - Luisella Righi
AU  - Silvia Novello
AU  - Benjamin Besse
PY  - 2026
DA  - 2026/11/04
JO  - Lancet Oncology
DO  - 10.1016/s1470-2045(25)00300-6
UR  - https://hal.science/hal-05851896v1
SN  - 1470-2045
SN  - 1474-5488
ER  -

Related

Cite